Charles River Laboratories International, Inc.
CRL
$138.79
-$2.57-1.82%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.71% | -1.08% | -1.64% | -3.19% | -1.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.71% | -1.08% | -1.64% | -3.19% | -1.73% |
| Cost of Revenue | -2.23% | 4.48% | -1.31% | 0.00% | 1.58% |
| Gross Profit | -3.59% | -11.43% | -2.21% | -8.42% | -7.36% |
| SG&A Expenses | -0.51% | 0.06% | 7.49% | -16.56% | 2.02% |
| Depreciation & Amortization | -8.63% | 21.17% | -5.33% | -5.85% | -6.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.12% | 4.15% | 0.31% | -3.91% | 1.33% |
| Operating Income | -6.27% | -37.95% | -11.62% | 0.57% | -16.96% |
| Income Before Tax | -63.66% | -203.87% | -19.16% | -7.00% | -24.44% |
| Income Tax Expenses | -58.82% | -115.41% | -15.72% | -13.10% | -9.44% |
| Earnings from Continuing Operations | -65.26% | -213.12% | -20.14% | -5.21% | -28.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 94.28% | 59.96% | -0.95% | 92.57% | -769.14% |
| Net Income | -62.17% | -214.65% | -20.29% | -3.03% | -34.72% |
| EBIT | -6.27% | -37.95% | -11.62% | 0.57% | -16.96% |
| EBITDA | -4.14% | -17.24% | -4.13% | 3.79% | -8.39% |
| EPS Basic | -61.60% | -215.69% | -21.58% | -7.85% | -35.14% |
| Normalized Basic EPS | -8.11% | -67.82% | -5.71% | 6.14% | -22.49% |
| EPS Diluted | -61.54% | -216.41% | -21.30% | -7.94% | -35.32% |
| Normalized Diluted EPS | -7.70% | -67.62% | -5.46% | 6.06% | -22.60% |
| Average Basic Shares Outstanding | -1.48% | -0.34% | 0.22% | 0.65% | 0.67% |
| Average Diluted Shares Outstanding | -1.91% | -0.94% | -0.05% | 0.74% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |